Cellectis (CLLS) Competitors $3.53 +0.03 (+0.86%) Closing price 04:00 PM EasternExtended Trading$3.52 0.00 (-0.14%) As of 04:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLLS vs. AVXL, PROK, AVBP, AKBA, MRVI, PRME, TBPH, DAWN, TYRA, and GYREShould you be buying Cellectis stock or one of its competitors? The main competitors of Cellectis include Anavex Life Sciences (AVXL), ProKidney (PROK), ArriVent BioPharma (AVBP), Akebia Therapeutics (AKBA), Maravai LifeSciences (MRVI), Prime Medicine (PRME), Theravance Biopharma (TBPH), Day One Biopharmaceuticals (DAWN), Tyra Biosciences (TYRA), and Gyre Therapeutics (GYRE). These companies are all part of the "pharmaceutical products" industry. Cellectis vs. Its Competitors Anavex Life Sciences ProKidney ArriVent BioPharma Akebia Therapeutics Maravai LifeSciences Prime Medicine Theravance Biopharma Day One Biopharmaceuticals Tyra Biosciences Gyre Therapeutics Cellectis (NASDAQ:CLLS) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability. Does the media prefer CLLS or AVXL? In the previous week, Anavex Life Sciences had 15 more articles in the media than Cellectis. MarketBeat recorded 16 mentions for Anavex Life Sciences and 1 mentions for Cellectis. Cellectis' average media sentiment score of 1.11 beat Anavex Life Sciences' score of 0.40 indicating that Cellectis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cellectis 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Anavex Life Sciences 3 Very Positive mention(s) 2 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders hold more shares of CLLS or AVXL? 63.9% of Cellectis shares are held by institutional investors. Comparatively, 31.6% of Anavex Life Sciences shares are held by institutional investors. 16.4% of Cellectis shares are held by company insiders. Comparatively, 11.0% of Anavex Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is CLLS or AVXL more profitable? Anavex Life Sciences has a net margin of 0.00% compared to Cellectis' net margin of -100.69%. Anavex Life Sciences' return on equity of -45.67% beat Cellectis' return on equity.Company Net Margins Return on Equity Return on Assets Cellectis-100.69% -68.05% -21.53% Anavex Life Sciences N/A -45.67%-40.21% Do analysts recommend CLLS or AVXL? Cellectis presently has a consensus target price of $4.00, suggesting a potential upside of 13.31%. Anavex Life Sciences has a consensus target price of $44.00, suggesting a potential upside of 357.86%. Given Anavex Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Anavex Life Sciences is more favorable than Cellectis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cellectis 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Anavex Life Sciences 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Which has more volatility and risk, CLLS or AVXL? Cellectis has a beta of 3.1, suggesting that its share price is 210% more volatile than the S&P 500. Comparatively, Anavex Life Sciences has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500. Which has stronger earnings & valuation, CLLS or AVXL? Cellectis has higher revenue and earnings than Anavex Life Sciences. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCellectis$49.22MN/A-$36.76M-$0.82-4.30Anavex Life SciencesN/AN/A-$43M-$0.57-16.86 SummaryCellectis beats Anavex Life Sciences on 8 of the 15 factors compared between the two stocks. Get Cellectis News Delivered to You Automatically Sign up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CLLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLLS vs. The Competition Export to ExcelMetricCellectisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$194.54M$3.36B$6.16B$10.58BDividend YieldN/A2.28%5.66%4.69%P/E Ratio-4.307.9965.0423.37Price / SalesN/A460.86612.06135.37Price / CashN/A46.3226.3031.10Price / Book1.509.9612.876.67Net Income-$36.76M-$52.42M$3.30B$276.23M7 Day Performance24.30%5.95%4.80%3.31%1 Month Performance31.72%11.59%8.11%10.76%1 Year Performance86.38%25.01%75.85%33.58% Cellectis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLLSCellectis1.4818 of 5 stars$3.53+0.9%$4.00+13.3%+84.8%$194.54M$49.22M-4.30290Positive NewsGap DownAVXLAnavex Life Sciences3.805 of 5 stars$8.65-0.1%$44.00+408.7%+78.0%$743.84MN/A-15.1840Positive NewsPROKProKidney2.7432 of 5 stars$2.48-0.4%$6.25+152.0%+61.7%$732.76M$80K-4.353AVBPArriVent BioPharma1.8871 of 5 stars$18.16+0.7%$39.14+115.5%-27.2%$731.46MN/A-4.5240News CoverageAKBAAkebia Therapeutics3.2815 of 5 stars$2.71-1.1%$6.75+149.1%+112.8%$726.50M$160.18M-15.94430Positive NewsMRVIMaravai LifeSciences3.5246 of 5 stars$2.83+0.4%$5.22+84.4%-60.8%$720.12M$259.18M-2.08610Positive NewsPRMEPrime Medicine3.13 of 5 stars$5.32+3.9%$8.92+67.6%+80.1%$715.93M$4.96M-2.60234Gap UpTBPHTheravance Biopharma3.3271 of 5 stars$14.43+2.6%$23.00+59.4%+77.9%$708.58M$64.38M60.13110Gap UpDAWNDay One Biopharmaceuticals3.1063 of 5 stars$6.99+3.2%$25.29+261.7%-43.6%$693.46M$131.16M-7.3660TYRATyra Biosciences2.331 of 5 stars$13.30+2.5%$31.86+139.5%-38.0%$691.26MN/A-7.4720Analyst UpgradeGYREGyre Therapeutics1.1583 of 5 stars$7.50+4.7%$18.00+140.0%-45.0%$689.60M$105.76M750.7540 Related Companies and Tools Related Companies AVXL Alternatives PROK Alternatives AVBP Alternatives AKBA Alternatives MRVI Alternatives PRME Alternatives TBPH Alternatives DAWN Alternatives TYRA Alternatives GYRE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLLS) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A Millionaire With SEVEN Clicks? $1,000 in just seven stocks in 2004 could have turned into a million-dolla...The Oxford Club | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectis S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellectis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
